Introduction
============

With the increasing number, availability, and rapid emergence of new information on antiretroviral (ARV) agents, a substantial complexity has been introduced into treatment regimens for patients with human immunodeficiency virus (HIV) infection.[@b1-tcrm-10-631] This may lead to low adherence to ARV regimens, which directly affects therapeutic efficacy. The risk of treatment failure, commonly associated with resistance to ARV agents, increases as adherence to therapy decreases.[@b2-tcrm-10-631] Clinical parameters used as predictors of therapeutic efficacy are CD4+ T-lymphocyte count and HIV viral load. CD4+ T-lymphocyte count is the most significant predictor of disease progression and survival. Lower CD4+ counts are associated with a greater risk of disease progression.[@b3-tcrm-10-631],[@b4-tcrm-10-631] CD4+ counts from 350 to 500 cells/mm^3^ are associated with risks of ≤5% across all age and HIV ribonucleic acid strata, whereas the risk of acquired immunodeficiency syndrome (AIDS) progression substantially increases at CD4+ counts \<350 cells/mm^3^. The greatest risk increase occurs as CD4+ counts fall to \<200 cells/mm^3^.[@b3-tcrm-10-631],[@b5-tcrm-10-631]

Due to ARV regimen complexity, many drug-related problems (DRPs) are detected in both inpatients and outpatients.[@b6-tcrm-10-631]--[@b8-tcrm-10-631] A DRP is an undesirable patient experience involving drug therapy that actually or potentially interferes with the desired patient outcome. The pharmacist is a key professional in detecting and preventing DRPs by providing information, answering questions, and helping the patient to improve his or her self-care. In this context, the function assigned to the pharmacist-educator is one of the most important to promote the rational use of medicines.[@b6-tcrm-10-631],[@b7-tcrm-10-631],[@b9-tcrm-10-631],[@b10-tcrm-10-631]

The public health system in Brazil is internationally recognized for its delivery of optimal treatment to patients with HIV at no cost since 1996. It is estimated that 217,000 patients have already been treated.[@b11-tcrm-10-631],[@b12-tcrm-10-631] Many similarities are observed when comparing Brazilian and American HIV treatment guidelines, suggesting that both can provide optimal care to patients with HIV ([Table 1](#t1-tcrm-10-631){ref-type="table"}).[@b4-tcrm-10-631],[@b13-tcrm-10-631]

However, suboptimal adherence to drug therapy greatly contributes to viral resistance and treatment failure.[@b14-tcrm-10-631] In an effort to slow viral resistance; improve treatment effectiveness; and identify, prevent, and solve DRPs, clinical pharmacist intervention can be of benefit to patients with HIV.[@b10-tcrm-10-631],[@b15-tcrm-10-631] Several studies with various population profiles demonstrated a significant decrease in medication errors at institutions where pharmacists performed interventions alongside the clinical team.[@b10-tcrm-10-631],[@b16-tcrm-10-631]--[@b19-tcrm-10-631] A systematic review and meta-analysis showed that pharmacists providing direct patient care had favorable effects across various patient outcomes, health care settings, and disease states.[@b20-tcrm-10-631]

Clinical pharmacy began to be officially discussed in Brazil in the mid-1990s. Since then, clinical pharmacy and pharmaceutical care services have been introduced in group discussions and research throughout the country in both private and public institutions, resulting in important developments in the field.[@b21-tcrm-10-631],[@b22-tcrm-10-631] Academically, general pharmacists are trained to work in various profession areas, and clinical pharmacists can now specialize. As is the case in many countries, more studies assessing the impact of clinical pharmacy services in Brazil are needed on patient outcomes and safety.[@b23-tcrm-10-631],[@b24-tcrm-10-631]

This article contributes to the literature in many ways. Its purpose is to verify the relevance of performing pharmacy care in patients with HIV infection through the analysis of its effect on DRPs, CD4+ T-lymphocyte counts, and HIV viral load.

Materials and methods
=====================

In this prospective controlled study, patients were selected by convenience sampling between February 2009 and August 2010 at the Hospital Dia--University of Campinas Teaching Hospital (Campinas, Brazil). The research was approved by the Research Ethics Committee of the Faculty of Medical Sciences, University of Campinas.

Eligibility criteria
--------------------

Outpatients with HIV or AIDS aged 18--60 years and with a body mass index of \<30 kg/m^2^ were eligible if they were receiving ARV treatment with no changes at the inclusion visit or within the previous 4 weeks. Patients aged \>60 years were not included in the study because higher HIV infection progression and mortality rates have been identified among older patients compared with younger patients.[@b25-tcrm-10-631] Additionally, advanced age is associated with a greater number of medications for comorbidities, drug interactions, adverse reactions, and toxicity.[@b26-tcrm-10-631] Obese patients were not included because they present higher incidences of hyperlipidemia, hypertension, and insulin resistance, and because some HIV medications, such as protease inhibitors, can cause weight gain and fat accumulation, it would not be possible to determine whether weight gain was related to the medication or to the background disease in such patients.[@b27-tcrm-10-631]--[@b30-tcrm-10-631]

Excluded from participation were patients who were prisoners, who were unable to return for appointments or examinations, who died during the study period, who had severe psychiatric disease that limited comprehension, who did not follow previously scheduled appointments, and who were pregnant.

Groups, outcome measures, and classifications
---------------------------------------------

Patients were assigned to an intervention group or a control group. On days when the clinical pharmacy team was in Hospital Dia for appointments, medical charts of patients being attended were analyzed for fit with the study criteria, and those eligible were assigned to the intervention group. On days when the clinical pharmacy staff was not in Hospital Dia, patients were evaluated for eligibility and assigned to the control which was subsequently revised by the clinical pharmacy team.

Patients in the intervention group were asked to attend appointments with a clinical pharmacist after their routine physician appointments during the study period. Those in the control group received the usual care without appointments with the clinical pharmacists.

For the intervention group, at least two pharmacist appointments of 30--60 minutes each were performed. The first appointment was named visit one. Visit two was defined as the second pharmacist appointment with new CD4+ count and HIV viral load results. Some patients attended more than one pharmacist appointment after visit one, but for study purposes, only visits defined as one and two were considered. For the control group, visits one and two were defined as medical appointments that included examination results. Patients in the intervention group who had fewer than two pharmacist appointments and patients in both groups who were referred to another health service during the study were excluded.

Pharmacist appointments began with data collection through patient interview regarding medical history. Besides patient reports about health and ongoing treatments, other information was obtained from family members or caregivers and other health professionals. The theoretical framework for the pharmaceutical appointment relied on Pharmacotherapy Workup, a process where pharmacists use rational decision-making to assess a patient's drug-related needs, identify drug therapy problems, develop a care plan, conduct follow-up evaluations, and ensure that all drug therapies are safe and effective.[@b31-tcrm-10-631] The Pharmacotherapy Workup was modified according to our institution's service limitations and research requirements. Forms used to record data and guide the pharmacist appointments were prepared by the study pharmacists.

The pharmacist team comprised two pharmacists responsible for performing the clinical pharmacist appointments and two pharmacists responsible for DRP analysis. The primary end point was the comparison between DRPs identified at baseline and at the end of the study for the intervention group. Secondary end points were the comparison between change in CD4+ and HIV viral load from baseline to study end in both the intervention and the control groups.

Before the pharmacist appointments, the patient's medical history was reviewed using his or her medical chart. The following data were collected for each intervention group patient: age, ethnicity, HIV diagnosis in years, HIV treatment in years, CD4+ count, HIV viral load, comorbidities, and ARV regimen. Patient symptoms, signs, complaints, medications in use, and self-reported nonadherence data were obtained through an interview during the pharmacist appointment. These data were analyzed by separate pharmacists on the team to identify and classify the DRPs related to all medications, including ARV therapy. For the control group, the same data were collected from the medical chart at the time when the patient was included in the study, but the pharmacist appointment was not performed, and additional data regarding medication were not collected; thus, the DRPs could not be accurately identified.

DRPs were individually identified and classified by two pharmacists, in seven categories: 1) unnecessary drug therapy: drug therapy is unnecessary because there is no clinical indication; 2) needs additional drug therapy: additional drug therapy is required to treat or prevent a medical condition; 3) ineffective drug: drug is not effective in producing the desired response; 4) dosage too low: dosage is too low to produce the desired response; 5) adverse drug reaction: drug causes an adverse reaction; 6) dosage too high: dosage results in undesirable effects; 7) noncompliance: the patient is not able or willing to take the drug regimen appropriately.[@b31-tcrm-10-631] After identifying DRPs, the clinical pharmacists developed a pharmacist intervention plan comprising measures to be taken by the patient and medical team in upcoming appointments. The three main pharmacist goals were to resolve DRPs, prevent DRPs, and encourage the adoption of healthy habits (quality-of-life intervention).

Pharmacist interventions consisted of guiding patients, mainly with regard to adherence to the prescribed therapeutic regimen, and suggesting medication changes to physicians when needed. Pharmacist interventions were performed in case of problems with dosage, drug--drug and drug--food interactions, side effects, and adverse reactions. Verbal and written information about pharmaceutical interventions was provided to the patients and physicians.

A community pharmacy specializing in ARV treatment, also located at the University of Campinas, was responsible for providing the ARV treatment.

Statistical analysis
--------------------

A 95% confidence interval (CI) was applied to determine the extent of variation in data. Collected data were analyzed using a paired *t*-test to compare primary and secondary end points before and after interventions. For nonparametric data and because of the small sample size, DRP reduction, total pharmacist interventions, increase of CD4+ T-lymphocyte count, and reduction in HIV viral load for the intervention group were analyzed by Spearman correlation test. A two-sided *P*\<0.05 was considered statistically significant for all tests.

Results
=======

A total of 115 patients with HIV infection from Hospital Dia were screened between February 2009 and August 2010. Among them, 111 patients met the study inclusion criteria and were assigned to either the intervention group (n=57) or control group (n=54). Four patients could not be included in the study because of obesity (n=3) and being older than 60 (n=1). Consent was obtained from all patients participating in the study. During the study, 12 patients in the intervention group were excluded: six were transferred to another health care center, and six did not attend at least two pharmacist appointments. From the control group, nine patients were excluded: seven were transferred to another health care center, and two died. Thus, the final sample included 90 patients (n=45 for both groups). The average interval between visit one and visit two for both groups was 5.47±3.94 months, and the average duration of each visit was 1 hour. The average number of pharmacist appointments per patient in the intervention group was 3.0±1.1 (range =2--5).

[Table 2](#t2-tcrm-10-631){ref-type="table"} shows the baseline characteristics of the control and intervention groups. The groups were similar in age, sex, ethnicity, time of HIV diagnosis, treatment, and laboratory baseline values. The intervention group presented with a mean basal CD4+ count of 260.7 cells/mm^3^, and the control group presented with 228.9 cells/mm^3^. Eighty-nine percent of intervention group patients versus 93% of control group patients presented with comorbidities.

[Table 3](#t3-tcrm-10-631){ref-type="table"} shows DRPs, the primary end point. At visit one, 5.2 (95% CI =4.1--6.2) potential DRPs per patient were found for a total of 227. Most of these DRPs (3.0 per patient) were due to adverse reactions. After pharmacist intervention, DRPs per patient decreased to 4.2 (95% CI =3.3--5.1, *P*=0.043), illustrating the relationship between potential DRPs observed before and after pharmacist intervention and their frequency in the study (in absolute numbers).

A total of 122 interventions were proposed, with an average of 2.7 interventions per patient. Among them, 33 (27%) were to solve DRPs, including 28 pharmacist--patient interventions. Seventy-nine (65%) interventions were to prevent DRPs, including 63 pharmacist--patient interventions. Ten (8%) interventions were related to improving quality of life. [Figure 1](#f1-tcrm-10-631){ref-type="fig"} shows the most-performed pharmacist interventions and prevalence of pharmacist--patient/physician interventions. All pharmacist interventions were accepted by physicians, and among patients, the interventions were well accepted during the appointments, but compliance with the interventions was not measured.

[Figure 2](#f2-tcrm-10-631){ref-type="fig"} shows a significant increase in the CD4+ T-lymphocyte count for the intervention group after the study period (*P*=0.015). However, no significant difference in CD4+ counts after the study was observed for the control group.

Variation of HIV viral load results before and after pharmacist interventions for both groups were not significant (intervention group, *P*=0.154; control group, *P*=0.226). At baseline, 46% of the intervention group and 19% of the control group had an HIV viral load of \<50 copies/mL; after the study period, these rates increased to 61% and 40%, respectively.

DRP reduction, total pharmacist interventions, increase of CD4+ T-lymphocyte count, and reduction in HIV viral load did not correlate significantly (data not shown).

Discussion
==========

Pharmacist contributions to the optimization of drug therapy may be evaluated through indirect measures (eg, DRPs) and direct measures, which provide the most conclusive evidence (eg, clinical outcomes).[@b32-tcrm-10-631] A study with 70 patients who received pharmacist interventions during a 4-year period showed that direct patient care led to an increase in treatment compliance and clinical benefits and demonstrated that an average of 1.7 interventions per patient were needed.[@b33-tcrm-10-631]

Data from the current study show that patients with HIV infection managed simultaneously by a clinical pharmacy team and their physicians benefited from a decrease in the number of DRPs. At visit one, a high number of potential DRPs per patient were found, which is consistent with a study where medical records were prospectively reviewed in 83 patients with HIV infection who received ARV therapy for 20 months; 176 DRPs were identified in 71 of these patients, including inappropriate prophylaxis for opportunistic infections, too-low and too-high dosages, adverse drug reactions due to ARV drugs, and drug--drug interactions between the ARV drug and another medication.[@b7-tcrm-10-631] In the current study, the most prevalent DRP identified was adverse reaction. Other researchers have also found high frequencies of inappropriate dosage and safety problems.[@b34-tcrm-10-631],[@b35-tcrm-10-631] One showed that the most common issues in hospitalized patients with HIV infection were contraindicated drug--drug combinations and dosing errors.[@b35-tcrm-10-631]

The current study shows that DRPs per patient decrease significantly with clinical pharmacist intervention, which is consistent with another study demonstrating that clinical pharmacist involvement leads to significantly more DRPs being identified compared with usual care.[@b36-tcrm-10-631] Other studies have demonstrated that clinical pharmacists not only can effectively identify, solve, and prevent clinically significant DRPs and their outcomes but also have assisted the multidisciplinary team in improving ARV treatment adherence and rational drug use and diminishing drug-related health problems.[@b33-tcrm-10-631],[@b36-tcrm-10-631],[@b37-tcrm-10-631]

The detection of DRP reduction, however, is not sufficient. It is also necessary to demonstrate positive clinical outcomes. The current study demonstrates that patients undergoing pharmaceutical care had a significant increase in CD4+ counts when compared before and after the study period, whereas the control group did not show this increase. This difference in CD4+ count was the most relevant between the study groups. In the intervention group, the difference between CD4+ counts at both measured moments (ie, visits one and two) was \~51.3 cells/mm^3^. Immunologic responses of 50 cells/mm^3^ had previously been correlated with a reduced risk of developing opportunistic infections,[@b38-tcrm-10-631] suggesting a trend toward improvement of ARV treatment adherence in the intervention group as previously demonstrated by other studies.[@b4-tcrm-10-631],[@b6-tcrm-10-631],[@b15-tcrm-10-631],[@b33-tcrm-10-631],[@b39-tcrm-10-631] Researchers demonstrated that patients with HIV under pharmaceutical care have significantly improved CD4+ counts, decreased HIV viral load, and fewer toxic effects related to ARV drugs.[@b39-tcrm-10-631] Toxicity reduction improves patient quality of life and treatment adherence.[@b40-tcrm-10-631]--[@b42-tcrm-10-631] A cohort study in 2,234 patients showed that those patients who had pharmacy team involvement in their care adhered more to ARV therapy than those who did not have pharmacy team involvement.[@b43-tcrm-10-631] On the contrary, the current study demonstrates that both the intervention and control groups had similar results relative to HIV viral load. Further studies are needed over a longer monitoring period to allow for a better analysis.

The clinical pharmacists in the current study performed \>70% of the pharmacist--patient intervention. This finding demonstrates that patients with HIV need orientation regarding ARV treatment, which clinical pharmacists are well qualified to provide.

This study is one of the first efforts in Brazil to analyze the contribution of a clinical pharmacy team to clinical and safety outcomes in patients with HIV receiving ARV therapy. We intentionally measured only clinical outcomes, such as CD4+ counts and DRPs, rather than subjective outcomes, such as quality of life, to show quantitatively the benefits of pharmaceutical care in this patient population.

This study suggests that pharmaceutical intervention can increase CD4+ T-lymphocyte counts and decrease DRPs. Aside from its limitations, the study contributes to the discussion of clinical care in both national and international health care scenarios. The study also shows the importance of an optimal pharmaceutical care plan and that the distribution of ARV treatments should be associated with educational initiatives. Further studies are encouraged to confirm the initiative of this program.

Limitations
-----------

This study has several limitations. First, the patients were allocated for control or intervention groups based on convenience sampling, which can lead to selection bias. Second, the pharmacists were not blinded, which may have influenced the DRP identification and quantification process. However, the pharmacists were not the same as those who interviewed the patients during their appointments, minimizing this influence. Third, it was not possible to quantify DRPs in the control group. Although the control group did not participate in pharmaceutical appointments, DRP quantification could have been obtained through medical chart revision. However, the medical charts were not complete and are not as useful for gathering accurate information as is a pharmaceutical appointment. Fourth, some relevant information that could contribute to the study was not obtained, such as pill count. Due to Hospital Dia characteristics and study requirements, all pharmacist appointments were performed by two pharmacists, which is unusual in pharmaceutical care services owing to financial issues. These research singularities were a result of study adaptations to the requirements of Hospital Dia. Finally, CD4+ counts and comorbidities were not identical in both study groups at inclusion. However, the difference between the groups regarding CD4+ count was not statistically significant. These limitations are already being addressed by the research team in current studies.
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![Pharmaceutical interventions performed by the clinical pharmacists.\
**Abbreviation:** DRP, drug-related problem.](tcrm-10-631Fig1){#f1-tcrm-10-631}

![Comparison of the mean CD4+ count before and after the study period for the control group (n=45) and intervention group (n=45).\
**Notes:** ^a^Student's *t*-test considering two-tailed test; ^b^95% confidence interval considered.](tcrm-10-631Fig2){#f2-tcrm-10-631}

###### 

Comparison of the Brazilian and United Stated guidelines for human immunodeficiency virus treatment in relation to drug-resistance testing at the time of antiretroviral therapy (ART) initiation, initiating ART in treatment-naïve patients, and initial combination regimens for antiretroviral-naïve patients

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                    Drug-resistance testing at the time of ART initiation                                                                                            Initiating ART in treatment-naïve patients                                                                                                                                                                                                                                       Initial combination regimens for antiretroviral-naïve patients
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------
  Brazil[@b4-tcrm-10-631]           People infected by partner in use of ART (recent or in the past); pregnant women with HIV infection                                              All patients with HIV infection with symptomatic HIV; active tuberculosis; CD4+ count ≤500 cells/mm^3^; coinfection with hepatitis B virus; pregnant women; established cardiovascular disease; AIDS-defining malignancies with no indication of chemotherapy or radiotherapy.   AZT/3TC + EFV or TDF/3TC + EFV, regarding each patient's characteristics and presence of renal dysfunction or anemia not related to HIV infection.

  United States[@b13-tcrm-10-631]   People with HIV infection at entry into care regardless of whether ART was initiated immediately or deferred/pregnant women with HIV infection   All patients with HIV infection, to reduce the risk of disease progression.                                                                                                                                                                                                      1\) Based on the NNRTI: EFV/TDF/FTC\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                      2) Based on PI/r: ATV/r + TDF/FTC or DRV/r + TDF/FTC\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                      3) Based on integrase inhibitor: RAL + TDF/FTC.
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AIDS, acquired immunodeficiency syndrome; ATV/r + TDF/FTC, atazanavir/ritonavir + tenofovir/emtricitabine; AZT/3TC, zidovudine/efavirenz; DRV/r + TDF/FTC, darunavir/ritonavir + tenofovir/emtricitabine; EFV, efavirenz; EFV/TDF/FTC, efavirenz/tenofovir/emtricitabine; HIV, human immunodeficiency virus; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI/r, protease inhibitors/ritonavir; RAL + TDF/FTC, raltegravir + tenofovir/emtricitabine; TDF/3TC, tenofovir/lamivudine.

###### 

Comparison of the initial characteristics (baseline) of the control group (n=45) and the intervention group (n=45)

  Characteristics                                                                     CG                     IG                     *P*-value[a](#tfn2-tcrm-10-631){ref-type="table-fn"}
  ----------------------------------------------------------------------------------- ---------------------- ---------------------- ------------------------------------------------------
  Age (average ± CI, years)                                                           41.5 (39.2--43.8)      42.0 (39.1--44.9)      0.778
  Men, % (n)                                                                          55.5 (25)              55.5 (25)              1.000
  Ethnicity, % (n)                                                                                                                  
   Caucasian                                                                          64.4 (29)              57.8 (26)              0.522
   Biracial                                                                           24.4 (11)              28.9 (13)              0.816
   Asian                                                                              0.0 (0)                2.2 (1)                0.320
   Black                                                                              11.1 (5)               11.1 (5)               1.000
  HIV diagnosis (average ± CI, years)                                                 8.3 (6.9--9.7)         8.7 (6.2--11.2)        0.758
  Treatment time (average ± CI, years)                                                7.5 (6.3--8.7)         6.7 (5.2--8.2)         0.409
  Tablets per day[b](#tfn3-tcrm-10-631){ref-type="table-fn"} (average ± CI, number)   8.6 (7.1--10.1)        8.6 (7.5--9.7)         0.961
  CD4+ basal lymphocytes (average ± CI, cells/mm³)                                    228.9 (164.4--293.5)   260.7 (175.8--345.6)   0.589
  Basal viral load \<50 copies/mm³ (%)                                                34.0                   44.0                   0.285
  Basal hemoglobin (average ± CI, g/dL)                                               12.4 (11.6--13.2)      12.7 (12.2--13.2)      0.411
  Presented comorbidities, % (n)                                                      93.3 (42)              88.8 (40)              0.464
   Hepatitis C                                                                        33.3 (15)              13.3 (6)               0.025
   Smoking                                                                            28.8 (13)              11.1 (5)               0.035
   Neurotoxoplasmosis                                                                 13.3 (6)               15.5 (7)               0.767
  Antiretroviral regimen, %                                                                                                         
   Zidovudine/lamivudine + efavirenz                                                  15.5                   15.4                   0.910
   Lamivudine + tenofovir + lopinavir/ritonavir                                       22.2                   7.7                    0.212
   Zidovudine/lamivudine + tenofovir + lopinavir/ritonavir                            11.1                   15.4                   0.753
   Zidovudine/lamivudine + lopinavir/ritonavir                                        11.1                   0.0                    0.198
   Lamivudine + tenofovir + efavirenz                                                 11.1                   15.4                   0.753
   Others                                                                             28.9                   46.1                   0.150

**Notes:**

Student's *t*-test considering two-tailed test

prescription medicines, not only antiretroviral agents.

**Abbreviations:** CG, control group: not assisted by the pharmacist; CI, confidence interval; HIV, human immunodeficiency virus; IG, intervention group: assisted by the pharmacist.

###### 

Comparison of drug-related problems before and after the pharmaceutical intervention

  DRPs Types         Before PI   After PI         *P*-value[a](#tfn5-tcrm-10-631){ref-type="table-fn"}                    
  ------------------ ----------- ---------------- ------------------------------------------------------ ---------------- -------
  Unnecessary        1           0.0 (0.0--0.1)   1                                                      0.0 (0.0--0.1)   1.000
  Additional         70          1.6 (1.2--2.0)   50                                                     1.3 (0.9--1.7)   0.016
  Ineffective        7           0.2 (0.1--0.3)   4                                                      0.1 (0.0--0.2)   0.183
  Dosage too low     3           0.1 (0.0--0.2)   0                                                      0.0 (0.0)        0.323
  Adverse reaction   111         2.9 (2.4--3.4)   96                                                     2.6 (2.1--3.1)   0.141
  Dosage too high    17          0.5 (0.3--0.7)   17                                                     0.5 (0.2--0.8)   1.000
  Noncompliance      18          0.5 (0.2--0.7)   17                                                     0.8 (0.3--0.8)   0.859
  Total              227         5.2 (4.1--6.2)   171                                                    4.2 (3.3--5.1)   0.043

**Note:**

Student's *t*-test considering two-tailed test

**Abbreviations:** CI, confidence interval; DRPs, drug-related problems; PI, pharmaceutical intervention.
